<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114232</article-id><article-id pub-id-type="publisher-id">ACM-41653</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_44460395.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  1例川崎病休克综合征的早期识别和治疗
  Early Recognition and Treatment of Kawasaki Disease Shock Syndrome in 1 Case
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>越</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>永伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>元霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院儿科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1615</fpage><lpage>1621</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨川崎病休克综合征(KDSS)的早期识别及治疗。方法：回顾性分析我院1例KDSS患儿的临床表现、治疗过程。结果：患儿，男，5月1天，确诊为KD，病程第6天出现KDSS，给予抗休克、抗炎治疗，病程第13天出现消化道症状，给予补液、调理肠道菌群、保护肠粘膜等治疗后病情好转，医嘱出院。结论：对于KD患儿出现血流动力学不稳定现象，应立即考虑到KDSS，并给予积极治疗，减轻冠脉损害。
    Objective: To investigate the early recognition and treatment of Kawasaki disease shock syndrome. Method: The clinical manifestations and treatment course of a child with Kawasaki disease shock syndrome were analyzed retrospectively. Result: The patient, male, was diagnosed as Kawasaki disease on five months and one day, and Kawasaki disease shock syndrome appeared on the 6th day of the course of disease. He was given anti-shock and anti-inflammatory treatment. On the 13th day of the course of disease, the child developed digestive tract symptoms, and was treated with fluid rehydration, intestinal flora conditioning, intestinal mucosa protection and other treatments, after which his condition improved. The doctor ordered his to be discharged. Conclusion: Kawasaki disease shock syndrome should be considered immediately and treated actively in children with KD with hemodynamic instability to alleviate coronary artery damage. 
  
 
</p></abstract><kwd-group><kwd>川崎病，休克综合征，消化道症状，糖皮质激素，血管活性药物, Kawasaki Disease</kwd><kwd> Shock Syndrome</kwd><kwd> Gastrointestinal Symptoms</kwd><kwd> Glucocorticoid</kwd><kwd> Vasoactive Drugs</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨川崎病休克综合征(KDSS)的早期识别及治疗。方法：回顾性分析我院1例KDSS患儿的临床表现、治疗过程。结果：患儿，男，5月1天，确诊为KD，病程第6天出现KDSS，给予抗休克、抗炎治疗，病程第13天出现消化道症状，给予补液、调理肠道菌群、保护肠粘膜等治疗后病情好转，医嘱出院。结论：对于KD患儿出现血流动力学不稳定现象，应立即考虑到KDSS，并给予积极治疗，减轻冠脉损害。</p></sec><sec id="s2"><title>关键词</title><p>川崎病，休克综合征，消化道症状，糖皮质激素，血管活性药物</p></sec><sec id="s3"><title>Early Recognition and Treatment of Kawasaki Disease Shock Syndrome in 1 Case</title><p>Yue Sun, Yongwei Gao, Yuanxia Li</p><p>Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/25-1572133x4_hanspub.png" /></p><p>Received: Mar. 12<sup>th</sup>, 2021; accepted: Apr. 5<sup>th</sup>, 2021; published: Apr. 19<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/25-1572133x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the early recognition and treatment of Kawasaki disease shock syndrome. Method: The clinical manifestations and treatment course of a child with Kawasaki disease shock syndrome were analyzed retrospectively. Result: The patient, male, was diagnosed as Kawasaki disease on five months and one day, and Kawasaki disease shock syndrome appeared on the 6<sup>th</sup> day of the course of disease. He was given anti-shock and anti-inflammatory treatment. On the 13<sup>th</sup> day of the course of disease, the child developed digestive tract symptoms, and was treated with fluid rehydration, intestinal flora conditioning, intestinal mucosa protection and other treatments, after which his condition improved. The doctor ordered his to be discharged. Conclusion: Kawasaki disease shock syndrome should be considered immediately and treated actively in children with KD with hemodynamic instability to alleviate coronary artery damage.</p><p>Keywords:Kawasaki Disease, Shock Syndrome, Gastrointestinal Symptoms, Glucocorticoid, Vasoactive Drugs</p><disp-formula id="hanspub.41653-formula22"><graphic xlink:href="//html.hanspub.org/file/25-1572133x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/25-1572133x7_hanspub.png" /> <img src="//html.hanspub.org/file/25-1572133x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>川崎病(Kawasaki disease, KD)是一种主要发生在5岁以下儿童的非特异性全身血管炎症性疾病，亚洲发病率最高 [<xref ref-type="bibr" rid="hanspub.41653-ref1">1</xref>]。冠状动脉病变为本病的严重并发症，目前认为Z值在2.0~2.5之间属于冠状动脉扩张，≥2.5说明存在动脉瘤 [<xref ref-type="bibr" rid="hanspub.41653-ref2">2</xref>]，已成为儿童获得性心脏病的主要原因。1975年Kato等报道了1例6月龄的KD患儿出现休克、心功能衰竭等严重并发症的病例 [<xref ref-type="bibr" rid="hanspub.41653-ref3">3</xref>]，此后伴有血流动力学改变的危重症KD病例陆续可见报道 [<xref ref-type="bibr" rid="hanspub.41653-ref4">4</xref>]。有研究者提出自从2019年新冠肺炎爆发以来，欧洲儿童发生KD合并血流动力学不稳定的人数更是显著增多 [<xref ref-type="bibr" rid="hanspub.41653-ref5">5</xref>]，对于这种出现休克表现的KD被称为是川崎病休克综合征(Kawasaki disease shock syndrome, KDSS)。它是KD的一种严重表现形式，患儿机体炎症反应更加剧烈、更容易出现多脏器功能损害。因其易被漏诊、误诊而延误治疗，遗留严重心脏损害而越来越为医学界，尤其是儿科医生所关注。现回顾分析我院近期收治的1例KDSS患儿的临床资料，为指导临床的早期识别和治疗提供参考。</p></sec><sec id="s6"><title>2. 病历资料</title><p>患儿，男，5月1天，以“发热4天，球结膜充血1天”之代诉入院。入院查体：T 39.0℃，P 136次/分，R32次/分，Wt 9 kg。颈部可触及数枚肿大淋巴结，最大约黄豆大小，压痛阳性，活动度可；双侧球结膜充血，无脓性分泌物；口唇潮红、皲裂、出血，咽充血，杨梅舌；肛周皮肤潮红，无脱皮；手掌、足底潮红，无硬性水肿。心肺腹及神经系统未查及异常。患儿临床表现及体征符合KD诊断标准。入院给予营养等对症支持治疗。</p><p>病程第5天给予静脉滴注丙种球蛋白(IVIG)。病程第6天患儿出现精神萎靡，全身皮肤粘膜发花，心音低钝，肝肋下2 cm，四肢末梢冰冷，心率190次/分，呼吸30次/分，血氧饱和度77%，血压65/30 mmHg。给予补充血容量、甲泼尼龙抗炎、多巴胺改善循环，并急查血常规、肾功、电解质、心肌酶、B型前脑尿钠肽检测、心肌损伤类检测等，各项化验检查结果的前后变化情况见表1。经积极处理后，患儿一般情况好转。辅助检查示：B型前脑尿钠肽19,989 pg/mL (0~125)，肌酸激酶同工酶0.814 ng/ml (&lt;4.87)，肌红蛋白 &lt; 21 ng/ml (28~72)，超敏肌钙蛋白T 11.46 ng/ml (&lt;14)；颈部淋巴结超声：双侧颈部淋巴结增大(右侧为著)；心脏超声示：静息状态下，左侧冠动脉与主动脉根部比值略增大，余未见异常。病程第13天，患儿出现腹泻，腹部X线示：腹部肠管扩张。予口服复方嗜酸乳杆菌片、蒙脱石散、口服补液盐，调理肠道菌群、保护肠粘膜、纠正电解质紊乱。病程第17天，患儿明显好转，查体：颈部可触及数枚绿豆大小肿大淋巴结；双侧球结膜无充血；口唇红润，咽无充血；腹软，肝脾未触及肿大，肠鸣音正常；肛周无蜕皮；手、足末梢未见膜状蜕皮，无硬肿，予以出院。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Changes in test indexes during treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >病程第3天</th><th align="center" valign="middle" >病程第5天</th><th align="center" valign="middle" >病程第6天</th><th align="center" valign="middle" >病程第8天</th></tr></thead><tr><td align="center" valign="middle" >白细胞&#215;10<sup>9</sup>/L</td><td align="center" valign="middle" >5.71</td><td align="center" valign="middle" >15.10</td><td align="center" valign="middle" >13.04</td><td align="center" valign="middle" >9.21</td></tr><tr><td align="center" valign="middle" >中性粒细胞%</td><td align="center" valign="middle" >61.80</td><td align="center" valign="middle" >78.90</td><td align="center" valign="middle" >80.70</td><td align="center" valign="middle" >16.80</td></tr><tr><td align="center" valign="middle" >血红蛋白g/L</td><td align="center" valign="middle" >120</td><td align="center" valign="middle" >107</td><td align="center" valign="middle" >104</td><td align="center" valign="middle" >92</td></tr><tr><td align="center" valign="middle" >血小板&#215;10<sup>9</sup>/L</td><td align="center" valign="middle" >428</td><td align="center" valign="middle" >336</td><td align="center" valign="middle" >300</td><td align="center" valign="middle" >521</td></tr><tr><td align="center" valign="middle" >C反应蛋白mg/L</td><td align="center" valign="middle" >147.30</td><td align="center" valign="middle" >93.35</td><td align="center" valign="middle" >238.16</td><td align="center" valign="middle" >44.39</td></tr><tr><td align="center" valign="middle" >PCT ng/ml</td><td align="center" valign="middle" >1.21</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.23</td></tr><tr><td align="center" valign="middle" >血钾mmol/L</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >3.70</td><td align="center" valign="middle" >3.12</td><td align="center" valign="middle" >4.40</td></tr><tr><td align="center" valign="middle" >血钠mmol/L</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >145.00</td><td align="center" valign="middle" >128.80</td><td align="center" valign="middle" >137.00</td></tr></tbody></table></table-wrap><p>表1. 治疗期间检验指标变化情况</p></sec><sec id="s7"><title>3. 讨论</title><p>2009年Kanegaye等提出KDSS的诊断标准：KD患儿出现持续性血压下降，收缩压低于相应年龄段正常平均血压值的20%或具有末梢循环灌注障碍的表现。1~12个月的儿童收缩压 &lt; 70 mmHg或1~12岁儿童收缩压 &lt; [70 + 2 &#215; 年龄(年)] mmHg即为低血压 [<xref ref-type="bibr" rid="hanspub.41653-ref6">6</xref>]。此外临床上还出现了收缩压正常、舒张压下降的KD表现，薛超超等人认为其介于KD和KDSS之间，为病程的过渡期 [<xref ref-type="bibr" rid="hanspub.41653-ref7">7</xref>]。国外文献报道KDSS占KD患儿的1.9%~7% [<xref ref-type="bibr" rid="hanspub.41653-ref8">8</xref>]，我国台湾地区KD患儿中约有1.78%~1.90%存在KDSS，且国外统计显示KDSS多见于女性，而国内研究显示男性多见 [<xref ref-type="bibr" rid="hanspub.41653-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.41653-ref10">10</xref>]。误差可能与人种、环境、样本例数、疾病早期表现不典型致临床认识不足而漏诊有关。</p><p>KDSS多出现在疾病早期，Chen等研究指出KDSS的休克出现时间为发热后第(3.3 &#177; 3.3) d [<xref ref-type="bibr" rid="hanspub.41653-ref11">11</xref>]，也有报道称为发热后(5.5 &#177; 2.1) d [<xref ref-type="bibr" rid="hanspub.41653-ref12">12</xref>]；李丰等报道KDSS的低血压出现在病程第2~9天 [<xref ref-type="bibr" rid="hanspub.41653-ref13">13</xref>]，结合KD诊断指南第6次修订版 [<xref ref-type="bibr" rid="hanspub.41653-ref14">14</xref>]，对于症状不典型患儿应先考虑到KD可能(见表2~4)，再进一步明确KDSS的诊断。并注意与脓毒症休克进行鉴别：脓毒症的休克处于疾病的失代偿期，此时多合并多器官功能衰竭，及时给予积极治疗，死亡率仍可高达44% [<xref ref-type="bibr" rid="hanspub.41653-ref15">15</xref>]。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Main clinical manifestations of Kawasaki diseas</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >1) 发热(不再强调发热5天以上)</th></tr></thead><tr><td align="center" valign="middle" >2) 双侧球结膜充血</td></tr><tr><td align="center" valign="middle" >3) 口唇及口腔的变化：唇红，草莓舌，口咽部黏膜弥漫性充血</td></tr><tr><td align="center" valign="middle" >4) 皮疹(可仅表现为卡介苗接种处发红)</td></tr><tr><td align="center" valign="middle" >5) 四肢末梢改变：急性期手足发红、肿胀，恢复期甲周蜕皮</td></tr><tr><td align="center" valign="middle" >6) 非化脓性颈部淋巴结肿大</td></tr></tbody></table></table-wrap><p>表2. KD主要临床表现</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Definition of complete or incomplete Kawasaki diseas</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >主要临床特征数量</th><th align="center" valign="middle" >冠状动脉异常</th><th align="center" valign="middle" >冠状动脉正常</th></tr></thead><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >cKD</td><td align="center" valign="middle" >Ckd</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >cKD</td><td align="center" valign="middle" >Ckd</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >cKD</td><td align="center" valign="middle" >iKD (伴其他有意义临床特征)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >iKD(排除其他发热性疾病)</td><td align="center" valign="middle" >iKD (伴其他有意义临床特征)</td></tr></tbody></table></table-wrap><p>表3. cKD或iKD的定义</p><p>注：cKD为完全性KD；iKD为不完全性KD。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Other significant clinical feature</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >病程早期肝转氨酶升高</th></tr></thead><tr><td align="center" valign="middle" >婴儿尿沉渣中白细胞增多</td></tr><tr><td align="center" valign="middle" >恢复期血小板增多</td></tr><tr><td align="center" valign="middle" >BNP或NT-proBNP升高</td></tr><tr><td align="center" valign="middle" >超声心动图示二尖瓣反流或心包积液</td></tr><tr><td align="center" valign="middle" >胆囊肿大(胆囊积液)</td></tr><tr><td align="center" valign="middle" >低白蛋白血症或低钠血症</td></tr></tbody></table></table-wrap><p>表4. 其他有意义临床特征</p><p>结合部分国内外文献报道，可认为KDSS患儿具有以下特点：① 女性比例高，平均年龄大于普通KD。但我国以男性患儿居多，高发年龄 ≥ 6岁或 ≤ 1岁；② 中性粒细胞比例、CRP、PCT更高；③ 低血小板血症、低血红蛋白血症、低钠血症、低钾血症；④ 心脏收缩功能障碍，冠状动脉扩张；⑤ 丙球无反应发生率高。有报道称大部分KDSS患儿还可出现胃肠道症状，不常见表现有胆囊积水、肠梗阻、无菌性脑膜炎等表现 [<xref ref-type="bibr" rid="hanspub.41653-ref16">16</xref>]。本例患儿男，5月1天，辅助检查示：N、CRP、PCT均升高，PLT、Hb、K、Na均有降低，ECG、心、腹B超未见明显异常，病程中还出现休克及腹泻表现，符合KDSS的临床表现。</p><p>KDSS的致病机制可能与毛细血管渗漏综合征、心脏收缩功能障碍、超抗原反应有关，它们共同作用导致KDSS的多器官损伤和衰竭 [<xref ref-type="bibr" rid="hanspub.41653-ref17">17</xref>]。</p><p>1) 毛细血管渗漏综合征：急性期炎症细胞可释放大量细胞因子、炎症介质、肿瘤坏死因子及血管内皮损伤因子，如IL-2可促使血管内皮生长因子高表达，血管通透性增高，血清Alb降低和渗出性水肿，低白蛋白血症造成胶体渗透压降低；同时血管内皮细胞还可促使一氧化氮合酶高表达而引起血管损伤 [<xref ref-type="bibr" rid="hanspub.41653-ref18">18</xref>]，导致血管紧张性失调和血管阻力降低；而脱水、抗利尿激素分泌异常、急性肾损伤及饮食欠佳等均可造成血钠降低；这些因素共同导致患儿血压下降，表现为非心源性休克。Natterer和Fang等认为炎症造成的血管通透性增高而导致毛细血管渗漏可能在KDSS的发病机制中起更重要的作用，因为部分KDSS患儿存在水肿，但并无明显心功能异常 [<xref ref-type="bibr" rid="hanspub.41653-ref19">19</xref>]。Park等也支持这一观点，他们考虑报道中部分所谓KDSS病例，其实是渗漏综合征患儿 [<xref ref-type="bibr" rid="hanspub.41653-ref20">20</xref>]。</p><p>2) 心脏收缩功能障碍：血流动力学异常、心肌缺血导致瓣膜、腱锁、乳头肌功能异常，超声心动图出现瓣膜反流、心室扩大等表现，心脏收缩功能障碍导致血压下降。脑钠肽(BNP)、肌钙蛋白(cTn)是目前反映早期心功能不全和心肌损伤的较敏感指标。仇慧仙等人 [<xref ref-type="bibr" rid="hanspub.41653-ref21">21</xref>] 的研究发现KDSS患儿存在血清NT-proBNP水平的明显升高，甚至达到普通KD患儿的8倍。经Logistic多因素回归分析可知，NT-proBNP水平明显提升是诱发KDSS的主要危险因素；并且KDSS患儿cTn-I的升高较KD患儿存在统计学意义。Kanegaye等认为KDSS的患儿存在心脏舒张和收缩功能损害 [<xref ref-type="bibr" rid="hanspub.41653-ref22">22</xref>]，王伟也支持这一观点，认为由于冠脉综合征或者心脏血管炎而导致心源性休克 [<xref ref-type="bibr" rid="hanspub.41653-ref23">23</xref>]。也有报道称KDSS患儿超声心动图没有心脏功能紊乱，不存在肌钙蛋白-I的升高 [<xref ref-type="bibr" rid="hanspub.41653-ref24">24</xref>]，说明KDSS患儿血压下降并不完全与心功能异常有关。</p><p>3) 感染：Shulman和Rowley报道的大量流行病学资料提示感染是KD发生的主要原因 [<xref ref-type="bibr" rid="hanspub.41653-ref25">25</xref>]。新冠病毒流行期间，一项意大利观察性队列研究显示当地KD的发病率较以往同期增加了近30倍，部分KDSS患儿核酸或血清抗体检测呈阳性，提示感染可能诱发KDSS [<xref ref-type="bibr" rid="hanspub.41653-ref26">26</xref>]。KDSS和脓毒症休克临床特点和免疫反应极为相似，后者是由细菌感染产生超级抗原介导的多系统障碍，所以有学者猜测细菌超级抗原可能与KDSS的致病机制有关，并认为在超抗原的刺激作用下，有遗传易感性的机体产生免疫紊乱，导致了KD血管炎的的发生 [<xref ref-type="bibr" rid="hanspub.41653-ref17">17</xref>]。关于超抗原的相关研究表明 [<xref ref-type="bibr" rid="hanspub.41653-ref27">27</xref>]：以T淋巴细胞免疫调节障碍为特征的免疫功能失调在KD的发病中发挥着重要作用。Matsuara和Fukaya报道KD患儿存在变形的T淋巴细胞，动物模型试验已经证明超级抗原反应 [<xref ref-type="bibr" rid="hanspub.41653-ref28">28</xref>]。CRP和PCT均是反映细菌感染的敏感指标，有文献报道，CRP升高水平与冠状动脉病变程度呈正相关 [<xref ref-type="bibr" rid="hanspub.41653-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41653-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.41653-ref30">30</xref>]，而PCT与KD严重程度、IVIG无反应、冠状动脉损害具有相关性 [<xref ref-type="bibr" rid="hanspub.41653-ref31">31</xref>]。结合KDSS患儿可出现临床表现重、对IVIG抵抗发生多、冠脉损害严重等，进一步猜测严重感染是引发KDSS的原因之一。</p><p>结合部分国内外文献及上述发病机制考虑KDSS患儿年龄较KD患儿大与较大儿童免疫功能相对完善，引起免疫反应更剧烈有关 [<xref ref-type="bibr" rid="hanspub.41653-ref21">21</xref>]。消化道症状可能与血流动力学衰竭导致肠系膜缺血、感染或非感染因素触发免疫介导的胃肠道血管炎、低钾血症等有关 [<xref ref-type="bibr" rid="hanspub.41653-ref32">32</xref>]，有研究证明胃肠道中存在产生超抗原的微生物，如产生热休克蛋白的细菌，热休克蛋白可模拟宿主体内的T细胞活化等免疫反应 [<xref ref-type="bibr" rid="hanspub.41653-ref18">18</xref>]。此外低钾可导致患儿出现厌食、恶心、呕吐、腹胀和肠蠕动消失等临床表现。胸腔积液和心包积液考虑与血浆蛋白渗漏导致的低白蛋白血症有关。IVIG无反应可能是由于全身免疫炎症反应更加剧烈所致，有研究指出，KD患儿外周血IL-6、IL-10和IFN-1水平升高是IVIG抵抗的标志物 [<xref ref-type="bibr" rid="hanspub.41653-ref33">33</xref>]，也有数据显示，CRP显著升高与IVIG抵抗的发生也存在联系 [<xref ref-type="bibr" rid="hanspub.41653-ref34">34</xref>]；可能与临床诊断困难、造成早期误诊漏诊，使用相对延后有关；也有可能是KDSS病例数少，纳入标准严格等，使临床诊断的KDSS患儿显示出IVIG抵抗的比例偏高。Kuo等报道KDSS患儿IL-6升高诱导铁调素下调与贫血有关 [<xref ref-type="bibr" rid="hanspub.41653-ref35">35</xref>]。本例患儿年龄较小，出现贫血可能与饮食欠佳、抽血化验次数频繁有关。</p><p>目前对于KDSS的治疗原则为抗休克、抗炎，即大剂量IVIG冲击的同时早期血管活性物质的应用、积极的液体复苏及小剂量糖皮质激素抗炎等对症治疗。IVIG可以减轻免疫反应的程度，缩短发热时间，从而在KD中发挥治疗作用。若静注人免疫球蛋白治疗后36 h仍发热(体温 &gt; 38℃)或退热后2~3 d再次发热并伴有至少1项KD的主要临床表现，则考虑对人免疫球蛋白无反应 [<xref ref-type="bibr" rid="hanspub.41653-ref36">36</xref>]。出现IVIG无反应时二次使用同剂量或半量的丙种球蛋白，部分患儿对二次丙球输注有效，仍无效者需给予激素、生物制剂、免疫抑制剂或血浆置换等治疗。糖皮质激素有稳定溶酶体膜、加强心肌收缩力、维持微循环血流动力学的稳定的作用 [<xref ref-type="bibr" rid="hanspub.41653-ref37">37</xref>]，有研究证明大剂量IVIG联合糖皮质激素治疗严重的KD患儿可降低冠状动脉病变(CAL)的发生率，2017年美国心脏协会提出对于部分IVIG耐药的重症KD患儿可以在初始治疗时联合应用小剂量激素，以降低CAL发生率 [<xref ref-type="bibr" rid="hanspub.41653-ref1">1</xref>]。而IVIG联合阿司匹林治疗对心里收缩力的恢复也有促进作用 [<xref ref-type="bibr" rid="hanspub.41653-ref38">38</xref>]。血管活性药物应用后仍不能改善循环、考虑存在血容量不足的情况下，可给予液体复苏。大量晶体液会降低血浆胶体渗透压，导致组织水肿加重而不作为首选。应在抗炎的基础上给予血浆白蛋白等胶体液，避免因毛细血管渗漏而加重组织水肿 [<xref ref-type="bibr" rid="hanspub.41653-ref31">31</xref>]。国外对于KD冠状动脉病变的治疗还包括波立维、华法林、低分子肝素、儿童冠状动脉旁路移植手术等 [<xref ref-type="bibr" rid="hanspub.41653-ref39">39</xref>]。</p><p>虽有小样本的观察资料随访结果提示KDSS预后良好，患儿患病后4~48个月内未发现有各脏器损伤的后遗症 [<xref ref-type="bibr" rid="hanspub.41653-ref40">40</xref>] [<xref ref-type="bibr" rid="hanspub.41653-ref41">41</xref>]，且急性期出现的瓣膜反流常能在早期恢复，但仍然存在远期心血管并发症风险，需对患儿进行长期随访。</p></sec><sec id="s8"><title>文章引用</title><p>孙 越,高永伟,李元霞. 1例川崎病休克综合征的早期识别和治疗Early Recognition and Treatment of Kawasaki Disease Shock Syndrome in 1 Case[J]. 临床医学进展, 2021, 11(04): 1615-1621. https://doi.org/10.12677/ACM.2021.114232</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41653-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">齐颖, 武宇辉, 等. 16例川崎病休克综合征临床分析[J]. 中国小儿急救医学, 2017, 24(12): 925-928.</mixed-citation></ref><ref id="hanspub.41653-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Pang, M.Y., Harris, J.E. and Eng, J.J. (2006) A Community-Based Upper Extremity Group Exercise Program Improves Motor Function and Performance of Functional Activities in Chronic Stroke: A Randomized Controlled Trial. Archives of Physical Medicine &amp; Rehabilitation, 87, 1-9. &lt;br&gt;https://doi.org/10.1016/j.apmr.2005.08.113</mixed-citation></ref><ref id="hanspub.41653-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kato, H., Koike, S., Yamamoto, M., et al. (1975) Coronary Aneurysms in Infants and Young Children with Acute Febrile Mucocutaneous Lymph Node Syndrome. The Journal of Pediatrics, 86, 892-898.  
&lt;br&gt;https://doi.org/10.1016/S0022-3476(75)80220-4</mixed-citation></ref><ref id="hanspub.41653-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">吕海涛. 川崎病休克综合征——儿科医师应重视的一种严重川崎病亚型. 中国小儿急救医学, 2020, 27(9): 657-660.</mixed-citation></ref><ref id="hanspub.41653-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Park, W.Y., et al. (2021) Clinical Aspects for Differential Diagnosis of Kawasaki Disease Shock Syndrome: A Case Control Study. BMC Pediatrics. &lt;br&gt;https://doi.org/10.1186/s12887-020-02488-w</mixed-citation></ref><ref id="hanspub.41653-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Newburger, J.W., Takahashi, M. and Burns, J.C. (2015) Kawasaki Disease. Journal of the American College of Cardiology, 67, 1738-1749. &lt;br&gt;https://doi.org/10.1016/j.jacc.2015.12.073</mixed-citation></ref><ref id="hanspub.41653-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">薛超超, 潘国权, 等. 不同血压类型川崎病患儿的临床特点分析. 医学研究杂志, 2017, 46(4): 78-82.</mixed-citation></ref><ref id="hanspub.41653-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kanegaye, J.T., Wilder, M.S., Molkara, D., et al. (2009) Recognition of a Kawasaki Disease Shock Syndrome. Pediatrics, 123, 783-789. &lt;br&gt;https://doi.org/10.1542/peds.2008-1871</mixed-citation></ref><ref id="hanspub.41653-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">单鸣凤, 梅小丽, 等. 儿童川崎病休克综合征的临床特点及相关因素. 中华实用儿科临床杂志, 2018, 33(9): 668-672.</mixed-citation></ref><ref id="hanspub.41653-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lin, M.T., Fu, C.M., Huang, S.K., et al. (2013) Population Based Study of Kawasaki Disease Shock Syndrome in Taiwan. The Pediatric Infectious Disease Journal, 32, 1384-1386. &lt;br&gt;https://doi.org/10.1097/INF.0b013e31829efae6</mixed-citation></ref><ref id="hanspub.41653-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chen, P.S., Chi, H., Huang, F.Y., et al. (2015) Clinical Manifestations of Kawasaki Disease Shock Syndrome: A Case-Control Study. Journal of Microbiology, Immunology and Infection, 48, 43-50.  
&lt;br&gt;https://doi.org/10.1016/j.jmii.2013.06.005</mixed-citation></ref><ref id="hanspub.41653-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Qiu, H.X., Xue, C.C., Chen, Q., et al. (2015) Clinical Manifestations and Risk Factors of Kawasaki Disease Shock Syndrome. Chinese Journal of Critical Care Medicine, 8, 230-234.</mixed-citation></ref><ref id="hanspub.41653-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">李丰, 张园海, 邵兰, 等. 川崎病并发休克6例临床分析. 临床儿科杂志, 2012, 30(10): 939-941.</mixed-citation></ref><ref id="hanspub.41653-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">泮思林, 刘芳, 罗刚, 等. 日本川崎病诊断指南第6次修订版. 中国实用儿科杂志, 2020, 35(11): 846-849.</mixed-citation></ref><ref id="hanspub.41653-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lamagni, T.L., Darenberg, J., Luca-Harari, B., et al. (2008) Epidemiology of Severe Strep Tococcus Pyogenes Disease in Europe. Journal of Clinical Microbiology, 46, 2359-2367. &lt;br&gt;https://doi.org/10.1128/JCM.00422-08</mixed-citation></ref><ref id="hanspub.41653-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">刘小惠, 彭宇, 蔡素芬. 川崎病1817例临床分析. 江西医学, 2019, 54(7): 806-807.</mixed-citation></ref><ref id="hanspub.41653-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">蒋道菊, 黄萍, 张丽, 等. 川崎病休克综合征的研究进展. 中华儿科杂志, 2016, 54(12): 961-963.</mixed-citation></ref><ref id="hanspub.41653-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">骆盈莹. 川崎病患儿心血管损害生物学标志物研究进展. 蛇志, 2020, 32(4): 492-494.</mixed-citation></ref><ref id="hanspub.41653-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Natterer, J., Perez, M.H. and Dibernardo, S. (2012) Capillary Leak Leading to Shock in Kawasaki Disease without Myocardial Days Function. Cardiology in the Young, 22, 349-352. &lt;br&gt;https://doi.org/10.1017/S1047951111001314</mixed-citation></ref><ref id="hanspub.41653-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Dominguez, S.R., Friedman, K., Seewald, R., et al. (2008) Kawasaki Disease in a Pediatric Intensive Care Unit: A Case-Control Study. Pediatrics, 122, 786-790. &lt;br&gt;https://doi.org/10.1542/peds.2008-1275</mixed-citation></ref><ref id="hanspub.41653-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">仇慧仙, 薛超超, 等. 川崎病休克综合征的临床特点及危险因素分析. 中华危重症医学杂志, 2015, 8(4): 230-234.</mixed-citation></ref><ref id="hanspub.41653-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Terai, M., Honda, T., Yasukawa, K., et al. (2003) Prognostic Impact of Vascular Leakage in Acute Kawasaki Disease. Circulation, 108, 325-330. &lt;br&gt;https://doi.org/10.1161/01.CIR.0000079166.93475.5F</mixed-citation></ref><ref id="hanspub.41653-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Wang, W., Zhu, W.H., Qi, Y.Q., et al. (2012) Cardiogenic Shock: Do Not for Get the Possibility of Kawasaki Disease. Turkish Journal of Pediatrics, 54, 86-89.</mixed-citation></ref><ref id="hanspub.41653-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Checchia, P.A., Borensztajn, J. and Shulman, S.T. (2001) Circulating Cardiac Troponin I Levels in Kawasaki Disease. Pediatric Cardiology, 22, 102-106. &lt;br&gt;https://doi.org/10.1007/s002460010170</mixed-citation></ref><ref id="hanspub.41653-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Shulmam, S.T. and Rowley, A.H. (2015) Kawasaki Disease: Insights into Pathogenesis and Approaches to Treatment. Nature Reviews Rheumatology, 11, 475-482. &lt;br&gt;https://doi.org/10.1038/nrrheum.2015.54</mixed-citation></ref><ref id="hanspub.41653-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Verdoni, L., Mazza, A., Gervasoni, A., et al. (2020) An Outbreak of Severe Kawasaki-Like Disease at the Italian Epicentre of the SARS-CoV-2 Epidemic: An Observational Cohort Study. The Lancet, 395, 1771-1778.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(20)31103-X</mixed-citation></ref><ref id="hanspub.41653-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Brogan, P.A., Shah, V., Klein, N., et al. (2004) Vbeta-Restricted T Cell Adherence to Endothelial Cells: A Mechanism for Superantigen Dependent Vascular Injury. Arthritis &amp; Rheumatology, 50, 589-597. &lt;br&gt;https://doi.org/10.1002/art.20021</mixed-citation></ref><ref id="hanspub.41653-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Matsubara, K. and Fukaya, T. (2007) The Role of Superantigens of Group A Streptococcus and Staphylococcus aureus in Kawasaki Disease. Current Opinion in Infectious Diseases, 20, 298-303.  
&lt;br&gt;https://doi.org/10.1097/QCO.0b013e3280964d8c</mixed-citation></ref><ref id="hanspub.41653-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Mitani, Y., Sawada, H., Hayakawa, H., et al. (2005) Elevated Levels of High-Sensitivity C-Reactive Protein and Serum Amyloid-A Late after Kawasaki Disease: Association between Inflammation and Late Coronary Sequelae in Kawasaki Disease. Circulation, 111, 38-43. &lt;br&gt;https://doi.org/10.1161/01.CIR.0000151311.38708.29</mixed-citation></ref><ref id="hanspub.41653-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Ou, C.Y., Tseng, Y.F., Lee, C.L., et al. (2009) Significant Relationship between Serum High-Sensitivity C-Reactive Protein, High Density Lipoprotein Cholesterol Levels and Children with Kawasaki Disease and Coronary Artery Lesions. Journal of the Formosan Medical Association, 108, 719-724. &lt;br&gt;https://doi.org/10.1016/S0929-6646(09)60395-8</mixed-citation></ref><ref id="hanspub.41653-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">刘力. 川崎病休克综合征的早期识别与处理. 中国小儿急救医学, 2020, 27(5): 324-329.</mixed-citation></ref><ref id="hanspub.41653-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Gatterre, P., Oualha, M., Dupic, L., et al. (2012) Kawasaki Disease: An Unexpected Etiology of Shock and Multiple Organ Dysfunction Syndrome. Intensive Care Medicine, 38, 872-878. &lt;br&gt;https://doi.org/10.1007/s00134-012-2473-8</mixed-citation></ref><ref id="hanspub.41653-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">李艳蝶, 郭莉, 等. 川崎病休克综合征临床特征及外周血细胞因子水平分析. 浙江医学, 2017, 39(21): 1852-1855.</mixed-citation></ref><ref id="hanspub.41653-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Tremoulet, A.H., Best, B.M., Song, S., et al. (2008) Resistance to Intravenous Immunoglobulin in Children with Kawasaki Disease. The Journal of Pediatrics, 153, 117-121. &lt;br&gt;https://doi.org/10.1016/j.jpeds.2007.12.021</mixed-citation></ref><ref id="hanspub.41653-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Kuo, H.C., Yang, Y.L., Chuang, J.H., et al. (2012) Inflammation-Induced Hepcidin Is Associated with the Development of Anemia and Coronary Artery Iesions in Kawasaki Disease. Journal of Clinical Immunology, 32, 746-752.  
&lt;br&gt;https://doi.org/10.1007/s10875-012-9668-1</mixed-citation></ref><ref id="hanspub.41653-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">王利, 耿玲玲, 李小青. 川崎病休克综合征1例. 中华临床医师杂志, 2020, 14(3): 238-240.</mixed-citation></ref><ref id="hanspub.41653-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">阚璇, 吴德静, 等. 川崎病休克综合征的临床研究进展. 天津医药, 2018, 46(6): 670-672.</mixed-citation></ref><ref id="hanspub.41653-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Newburger, J.W., Sanders, S.P., Burns, J.C., et al. (1989) Left Ventricular Contractility and Function in Kawasaki Syndrome. Effect of Intravenous Gamma-Globulin. Circulation, 79, 1237-1246.  
&lt;br&gt;https://doi.org/10.1161/01.CIR.79.6.1237</mixed-citation></ref><ref id="hanspub.41653-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">刘芳, 赵趣鸣, 等. MDT在重症川崎病中的应用. 中华医学信息导报, 2020, 35(24): 21.</mixed-citation></ref><ref id="hanspub.41653-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Qiu, H., Li, C., He, Y., et al. (2019) Association between Left Ventricular Rejection Fraction and Kawasaki Disease Shock Syndrome. Cardiology in the Young, 29, 178-184. &lt;br&gt;https://doi.org/10.1017/S1047951118002056</mixed-citation></ref><ref id="hanspub.41653-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Gamez-Gonzalez, L.B., Moribe-Quintero, I., Cisneros-Castolo, M., et al. (2018) Kawasaki Disease Shock Syndrome: Unique and Severe Subtype of Kawasaki Disease. Pediatrics International, 60, 781-790.  
&lt;br&gt;https://doi.org/10.1111/ped.13614</mixed-citation></ref></ref-list></back></article>